Haleon plc (HLN)vsHarrow Health Inc (HROW)
HLN
Haleon plc
$9.74
+0.41%
HEALTHCARE · Cap: $44.83B
HROW
Harrow Health Inc
$36.35
+3.27%
HEALTHCARE · Cap: $2.01B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 4311% more annual revenue ($11.03B vs $250.04M). HLN leads profitability with a 15.1% profit margin vs -2.0%. HLN earns a higher WallStSmart Score of 58/100 (C).
HLN
Buy58
out of 100
Grade: C
HROW
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.3%
Fair Value
$22.93
Current Price
$9.74
$13.19 discount
Intrinsic value data unavailable for HROW.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 92.0% YoY
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Revenue surging 45.4% year-over-year
Strong operational efficiency at 20.6%
Areas to Watch
Expensive relative to growth rate
0.6% revenue growth
Trading at 28.6x book value
ROE of -9.6% — below average capital efficiency
Earnings declined 64.0%
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on EPS Growth, Operating Margin, Free Cash Flow. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bull Case : HROW
The strongest argument for HROW centers on Revenue Growth, Operating Margin. Revenue growth of 45.4% demonstrates continued momentum.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth.
Bear Case : HROW
The primary concerns for HROW are Price/Book, Return on Equity, EPS Growth.
Key Dynamics to Monitor
HLN profiles as a value stock while HROW is a hypergrowth play — different risk/reward profiles.
HLN carries more volatility with a beta of 0.25 — expect wider price swings.
HROW is growing revenue faster at 45.4% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
HLN scores higher overall (58/100 vs 37/100), backed by strong 15.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company focused on delivering innovative health solutions across critical segments including oral care, pain relief, respiratory health, and dietary supplements. Formed from the spin-off of GlaxoSmithKline, Haleon boasts a strong portfolio of well-established brands, such as Sensodyne, Panadol, and Voltaren, solidifying its presence in the lucrative consumer health market. With a commitment to sustainability and consumer-driven innovation, the company is well-positioned to enhance health outcomes on a global scale while driving growth and delivering shareholder value through strategic investments and product advancements.
Visit Website →Harrow Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Harrow Health, Inc. is an ophthalmology-focused healthcare company. The company is headquartered in San Diego, California.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?